Secondary prevention in thrombotic antiphospholipid syndrome

被引：11
|
作者：
Pengo, V. [1 ]
Denas, G. [1 ]
Banzato, A. [1 ]
Bison, E. [1 ]
Bracco, A. [1 ]
Facchinetti, M. [2 ]
Hoxha, A. [2 ]
Ruffatti, A. [2 ]
机构：
[1] Univ Padua, Thrombosis Ctr, Dept Cardiac Thorac & Vasc Sci, I-35128 Padua, Italy
[2] Univ Padua, Rheumatol Unit, Dept Med, I-35128 Padua, Italy
来源：
LUPUS | 2012年 / 21卷 / 07期
关键词：
antiphospholipid; prevention; drugs; thrombosis; RECURRENT THROMBOSIS; THERAPY; INTENSITY; WARFARIN; RISK;
D O I：
10.1177/0961203312444773
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Secondary prevention of venous thromboembolism in antiphospholipid syndrome (APS) is usually made using vitamin K antagonists (VKAs) to maintain an international normalized ratio (INR) between 2.0 and 3.0. The optimal intensity of anticoagulation was determined in two prospective randomized controlled trials, both excluding the benefit of more intense anticoagulation. The same regimen is also recommended in patients with APS and arterial thromboembolism as aspirin does not appear to protect against recurrences. The duration of treatment is usually indefinite because of a substantial risk of recurrence. Lupus (2012) 21, 734-735.
引用
收藏
页码：734 / 735
页数：2
相关论文
共 50 条
  • [21] Thrombotic Antiphospholipid Syndrome and Direct Oral Anticoagulants: Unmet Needs and Review of the Literature
    Marco-Rico, Ana
    Marco-Vera, Pascual
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2023, 49 (07) : 736 - 743
  • [22] Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome
    Arachchillage, D. R. J.
    Mackie, I. J.
    Efthymiou, M.
    Isenberg, D. A.
    Machin, S. J.
    Cohen, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (07) : 1264 - 1273
  • [23] Rethinking the use of direct oral anticoagulants for secondary thromboprophylaxis in patients with thrombotic antiphospholipid syndrome
    Franco-Moreno, Anabel
    Izquierdo-Martinez, Aida
    Ancos-Aracil, Cristina
    DRUG DISCOVERIES AND THERAPEUTICS, 2024, 18 (04) : 213 - 219
  • [24] Thrombotic Management of Antiphospholipid Syndrome: Towards Novel Targeted Therapies
    Islam, Md. Asiful
    Alam, Fahmida
    Wong, Kah Keng
    Kamal, Mohammad Amjad
    Gan, Siew Hua
    CURRENT VASCULAR PHARMACOLOGY, 2017, 15 (04) : 313 - 326
  • [25] Biochemical Markers with Low-grade Inflammation as Predictors of Thrombotic Events in Antiphospholipid Syndrome
    Gavris, Claudia
    Poroch, Vladimir
    Simion, Laurentiu
    Baracan, Adrian
    Toader, Elena
    Pascu, Alina Mihaela
    REVISTA DE CHIMIE, 2017, 68 (07): : 1586 - 1590
  • [26] Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus
    Kotzen, Elizabeth S.
    Roy, Sanjeet
    Jain, Koyal
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2019, 26 (05) : 376 - 386
  • [27] Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies
    Wolfgang Miesbach
    Inge Scharrer
    Ronald Asherson
    Clinical Rheumatology, 2006, 25 : 840 - 844
  • [28] Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies
    Miesbach, Wolfgang
    Scharrer, Inge
    Asherson, Ronald
    CLINICAL RHEUMATOLOGY, 2006, 25 (06) : 840 - 844
  • [29] Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome
    Belizna, Cristina
    AUTOIMMUNITY REVIEWS, 2015, 14 (04) : 358 - 362
  • [30] New oral anticoagulants in thrombotic antiphospholipid syndrome
    Chighizola, C. B.
    Moia, M.
    Meroni, P. L.
    LUPUS, 2014, 23 (12) : 1279 - 1282
12345